## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.1% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($122.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)**
- Source: Simply Wall Street | 20260103T130727 | Bullish | Relevance: 100%
- Abbott Laboratories (NYSE:ABT) is showing encouraging trends in its Returns on Capital Employed (ROCE). Over the last five years, ROCE has increased by 62% while capital employed remained constant, indicating improved efficiency without significant additional investment. Although the stock has only returned 22% to shareholders in the last five years, the promising fundamentals suggest it could be an overlooked opportunity worth further investigation.

**2. Abbott unveils new FreeStyle Libre app feature for mealtime decisions**
- Source: MassDevice | 20260105T170153 | Bullish | Relevance: 100%
- Abbott has launched Libre Assist, a new feature within its FreeStyle Libre app designed to help people with diabetes understand how different foods impact their glucose levels. Unlike traditional food logging apps, Libre Assist provides feedback before meals, enabling more informed dietary choices. This new offering was unveiled at CES 2026 and provides a similar functionality to Dexcom's AI-powered meal logging system.

**3. Abbott Laboratories (NYSE:ABT) Price Target Raised to $169.00**
- Source: MarketBeat | 20260105T151830 | Bullish | Relevance: 100%
- Barclays has increased its price target for Abbott Laboratories (NYSE:ABT) to $169.00 from $162.00, reiterating an "overweight" rating and suggesting a 36.97% upside. The company's average analyst rating is a "Moderate Buy" with a consensus target of $147.37, following a quarter where Abbott met EPS expectations and saw 6.9% year-over-year revenue growth. Institutional investors have significantly increased their stakes in ABT, indicating strong confidence in the healthcare product maker.

**4. Railway Pension Investments Ltd Reduces Stock Holdings in Abbott Laboratories $ABT**
- Source: MarketBeat | 20260105T122959 | Somewhat-Bullish | Relevance: 100%
- Railway Pension Investments Ltd significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 67.6% in Q3, selling 156,200 shares and retaining 74,700 shares valued at $10.005 million. Despite this reduction, analysts maintain a "Moderate Buy" rating for ABT with an average target price of $147, and the company recently reported Q3 EPS in line with estimates and increased its quarterly dividend. Other institutional investors, such as Carr Financial Group Corp and Tortoise Investment Management LLC, made smaller adjustments to their holdings.

**5. Synergy Asset Management LLC Sells 40,094 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20260104T113636 | Somewhat-Bullish | Relevance: 100%
- Synergy Asset Management LLC significantly reduced its stake in Abbott Laboratories by selling 40,094 shares, leaving it with 1,964 shares valued at $263,000. This comes as Abbott Laboratories reported strong Q3 earnings, meeting consensus estimates with $1.30 EPS and $11.37 billion in revenue, and raised its quarterly dividend to $0.63. The company maintains a "Moderate Buy" consensus rating among analysts with an average price target of $147.00.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $169 | $162 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.3x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $220.1B |
| Beta | 0.72 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.3 |
| Current P/E | 24.5 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.8% to 1.1% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 53. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.10% (CS: 54) | Neutral |
| RSI_14 | 53.0 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 0.973x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $126.47
- **Stop Loss:** $122.13 (3.4% risk)
- **Target:** $130.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 198
- **Position Value:** $25,041.06
- **Portfolio %:** 25.04%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*